Search research articles
Contact Us
Filters
Showing results (101-110 of 137) with videos related to
Page
of 14
Sort By:
American Journal of Hematology
|
August 26, 2021
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma
Noa Biran, Elli Gourna Paleoudis, Rena Feinman, et al.
Leukemia & Lymphoma
|
September 23, 2023
Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma
Andrew Ip, Alessandra Petrillo, Alexandra Della Pia, et al.
Leukemia & Lymphoma
|
January 5, 2025
Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis
Gaurav Varma, Lindsay Fogel, Beth Gordon, et al.
Journal of the National Cancer Institute
|
April 6, 2021
Response to Dekker, Stege, and Versteeg
Jeanne S Mandelblatt, Xingtao Zhou, Brent J Small, et al.
Plos One
|
December 1, 2022
Anti-spike antibody response to the COVID vaccine in lymphoma patients
Alexandra Della Pia, Gee Youn Geeny Kim, Andrew Ip, et al.
Human Molecular Genetics
|
May 24, 2021
Erratum to: Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases
Alan J Fowler, Michaeline Hebron, Kaluvu Balaraman, et al.
Medrxiv : the Preprint Server for Health Sciences
|
July 3, 2026
Survival benefits of varying physical activity levels in a heterogeneous colorectal cancer cohort: The Disparities and Cancer Epidemiology (DANCE) study
Sarah M Lima, Chiranjeev Dash, Jaeil Ahn, et al.
Journal of the National Cancer Institute
|
January 23, 2021
Deficit Accumulation Frailty Trajectories of Older Breast Cancer Survivors and Non-Cancer Controls: The Thinking and Living With Cancer Study
Jeanne S Mandelblatt, Xingtao Zhou, Brent J Small, et al.
Human Molecular Genetics
|
August 11, 2020
Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases
Alan J Fowler, Michaeline Hebron, Kaluvu Balaraman, et al.
Haematologica
|
April 3, 2025
A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma
Noa Biran, Eli Zolotov, David Vesole, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 137) with videos related to
Sort By:
Page
of 14
American Journal of Hematology
|
August 26, 2021
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma
Noa Biran, Elli Gourna Paleoudis, Rena Feinman, et al.
Leukemia & Lymphoma
|
September 23, 2023
Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma
Andrew Ip, Alessandra Petrillo, Alexandra Della Pia, et al.
Leukemia & Lymphoma
|
January 5, 2025
Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis
Gaurav Varma, Lindsay Fogel, Beth Gordon, et al.
Journal of the National Cancer Institute
|
April 6, 2021
Response to Dekker, Stege, and Versteeg
Jeanne S Mandelblatt, Xingtao Zhou, Brent J Small, et al.
Plos One
|
December 1, 2022
Anti-spike antibody response to the COVID vaccine in lymphoma patients
Alexandra Della Pia, Gee Youn Geeny Kim, Andrew Ip, et al.
Human Molecular Genetics
|
May 24, 2021
Erratum to: Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases
Alan J Fowler, Michaeline Hebron, Kaluvu Balaraman, et al.
Medrxiv : the Preprint Server for Health Sciences
|
July 3, 2026
Survival benefits of varying physical activity levels in a heterogeneous colorectal cancer cohort: The Disparities and Cancer Epidemiology (DANCE) study
Sarah M Lima, Chiranjeev Dash, Jaeil Ahn, et al.
Journal of the National Cancer Institute
|
January 23, 2021
Deficit Accumulation Frailty Trajectories of Older Breast Cancer Survivors and Non-Cancer Controls: The Thinking and Living With Cancer Study
Jeanne S Mandelblatt, Xingtao Zhou, Brent J Small, et al.
Human Molecular Genetics
|
August 11, 2020
Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases
Alan J Fowler, Michaeline Hebron, Kaluvu Balaraman, et al.
Haematologica
|
April 3, 2025
A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma
Noa Biran, Eli Zolotov, David Vesole, et al.
Page
of 14